Association between urologic malignancies and end-stage renal disease: A meta-analysis

Panagiotis Kompotiatis, Charat Thongprayoon, Sandhya Manohar, Wisit Cheungpasitporn, Maria L. Gonzalez Suarez, Iasmina M. Craici, Michael A. Mao, Sandra Herrmann

Research output: Contribution to journalArticle

Abstract

Aim: Previous studies have suggested a higher incidence of urologic malignancies in end-stage renal disease (ESRD) patients. However, incidence trends of urologic malignancies in ESRD patients remain unclear. The aims of the present study were: (i) to investigate the pooled incidence/incidence trends; and (ii) to assess the risk of urologic malignancies in ESRD patients. Methods: A literature search was conducted using MEDLINE, EMBASE and Cochrane Database from inception through April 2017. Studies that reported incidence or odds ratios of urologic malignancies among ESRD patients were included. Pooled odds ratios (OR) and 95%CI were calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067687). Results: Nineteen observational studies with 1 931 073 ESRD patients were enrolled. The pooled estimated incidence of kidney cancer and urothelial cancers (carcinomas of the bladder, ureters, and renal pelvis) in ESRD patients were 0.3% (95%CI: 0.2–0.5%) and 0.5% (95%CI: 0.3–0.8%), respectively. Meta-regression showed significant positive correlation between incidence of urologic malignancies in ESRD patients and year of study (slopes = +0.05 and +0.07, P < 0.001 for kidney cancer and urothelial cancers, respectively). Compared to non-ESRD status, ESRD was significantly associated with both kidney cancer (pooled OR 6.04; 95% CI 4.70–7.77) and urothelial cancers (pooled OR 4.37; 95% CI 2.40–7.96). Conclusion: Our study demonstrates a significant association between ESRD and urologic malignancies. The overall estimated incidence rates of kidney cancer and urothelial cancers are 0.4% and 0.5%, respectively. There is a significant positive correlation between the incidence of urologic malignancies and year of study.

LanguageEnglish (US)
Pages65-73
Number of pages9
JournalNephrology
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Chronic Kidney Failure
Meta-Analysis
Kidney Neoplasms
Incidence
Neoplasms
Odds Ratio
Kidney Pelvis
Ureter
Urinary Bladder Neoplasms
MEDLINE
Observational Studies
Cohort Studies
Databases
Carcinoma
Kidney

Keywords

  • bladder cancer
  • end-stage kidney disease
  • kidney cancer
  • meta-analysis
  • urologic malignancies

ASJC Scopus subject areas

  • Nephrology

Cite this

Kompotiatis, P., Thongprayoon, C., Manohar, S., Cheungpasitporn, W., Gonzalez Suarez, M. L., Craici, I. M., ... Herrmann, S. (2019). Association between urologic malignancies and end-stage renal disease: A meta-analysis. Nephrology, 24(1), 65-73. https://doi.org/10.1111/nep.13209

Association between urologic malignancies and end-stage renal disease : A meta-analysis. / Kompotiatis, Panagiotis; Thongprayoon, Charat; Manohar, Sandhya; Cheungpasitporn, Wisit; Gonzalez Suarez, Maria L.; Craici, Iasmina M.; Mao, Michael A.; Herrmann, Sandra.

In: Nephrology, Vol. 24, No. 1, 01.01.2019, p. 65-73.

Research output: Contribution to journalArticle

Kompotiatis, P, Thongprayoon, C, Manohar, S, Cheungpasitporn, W, Gonzalez Suarez, ML, Craici, IM, Mao, MA & Herrmann, S 2019, 'Association between urologic malignancies and end-stage renal disease: A meta-analysis', Nephrology, vol. 24, no. 1, pp. 65-73. https://doi.org/10.1111/nep.13209
Kompotiatis P, Thongprayoon C, Manohar S, Cheungpasitporn W, Gonzalez Suarez ML, Craici IM et al. Association between urologic malignancies and end-stage renal disease: A meta-analysis. Nephrology. 2019 Jan 1;24(1):65-73. https://doi.org/10.1111/nep.13209
Kompotiatis, Panagiotis ; Thongprayoon, Charat ; Manohar, Sandhya ; Cheungpasitporn, Wisit ; Gonzalez Suarez, Maria L. ; Craici, Iasmina M. ; Mao, Michael A. ; Herrmann, Sandra. / Association between urologic malignancies and end-stage renal disease : A meta-analysis. In: Nephrology. 2019 ; Vol. 24, No. 1. pp. 65-73.
@article{1c52467d9bff4a2e8bc308a58a6543c3,
title = "Association between urologic malignancies and end-stage renal disease: A meta-analysis",
abstract = "Aim: Previous studies have suggested a higher incidence of urologic malignancies in end-stage renal disease (ESRD) patients. However, incidence trends of urologic malignancies in ESRD patients remain unclear. The aims of the present study were: (i) to investigate the pooled incidence/incidence trends; and (ii) to assess the risk of urologic malignancies in ESRD patients. Methods: A literature search was conducted using MEDLINE, EMBASE and Cochrane Database from inception through April 2017. Studies that reported incidence or odds ratios of urologic malignancies among ESRD patients were included. Pooled odds ratios (OR) and 95{\%}CI were calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067687). Results: Nineteen observational studies with 1 931 073 ESRD patients were enrolled. The pooled estimated incidence of kidney cancer and urothelial cancers (carcinomas of the bladder, ureters, and renal pelvis) in ESRD patients were 0.3{\%} (95{\%}CI: 0.2–0.5{\%}) and 0.5{\%} (95{\%}CI: 0.3–0.8{\%}), respectively. Meta-regression showed significant positive correlation between incidence of urologic malignancies in ESRD patients and year of study (slopes = +0.05 and +0.07, P < 0.001 for kidney cancer and urothelial cancers, respectively). Compared to non-ESRD status, ESRD was significantly associated with both kidney cancer (pooled OR 6.04; 95{\%} CI 4.70–7.77) and urothelial cancers (pooled OR 4.37; 95{\%} CI 2.40–7.96). Conclusion: Our study demonstrates a significant association between ESRD and urologic malignancies. The overall estimated incidence rates of kidney cancer and urothelial cancers are 0.4{\%} and 0.5{\%}, respectively. There is a significant positive correlation between the incidence of urologic malignancies and year of study.",
keywords = "bladder cancer, end-stage kidney disease, kidney cancer, meta-analysis, urologic malignancies",
author = "Panagiotis Kompotiatis and Charat Thongprayoon and Sandhya Manohar and Wisit Cheungpasitporn and {Gonzalez Suarez}, {Maria L.} and Craici, {Iasmina M.} and Mao, {Michael A.} and Sandra Herrmann",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/nep.13209",
language = "English (US)",
volume = "24",
pages = "65--73",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Association between urologic malignancies and end-stage renal disease

T2 - Nephrology

AU - Kompotiatis, Panagiotis

AU - Thongprayoon, Charat

AU - Manohar, Sandhya

AU - Cheungpasitporn, Wisit

AU - Gonzalez Suarez, Maria L.

AU - Craici, Iasmina M.

AU - Mao, Michael A.

AU - Herrmann, Sandra

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: Previous studies have suggested a higher incidence of urologic malignancies in end-stage renal disease (ESRD) patients. However, incidence trends of urologic malignancies in ESRD patients remain unclear. The aims of the present study were: (i) to investigate the pooled incidence/incidence trends; and (ii) to assess the risk of urologic malignancies in ESRD patients. Methods: A literature search was conducted using MEDLINE, EMBASE and Cochrane Database from inception through April 2017. Studies that reported incidence or odds ratios of urologic malignancies among ESRD patients were included. Pooled odds ratios (OR) and 95%CI were calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067687). Results: Nineteen observational studies with 1 931 073 ESRD patients were enrolled. The pooled estimated incidence of kidney cancer and urothelial cancers (carcinomas of the bladder, ureters, and renal pelvis) in ESRD patients were 0.3% (95%CI: 0.2–0.5%) and 0.5% (95%CI: 0.3–0.8%), respectively. Meta-regression showed significant positive correlation between incidence of urologic malignancies in ESRD patients and year of study (slopes = +0.05 and +0.07, P < 0.001 for kidney cancer and urothelial cancers, respectively). Compared to non-ESRD status, ESRD was significantly associated with both kidney cancer (pooled OR 6.04; 95% CI 4.70–7.77) and urothelial cancers (pooled OR 4.37; 95% CI 2.40–7.96). Conclusion: Our study demonstrates a significant association between ESRD and urologic malignancies. The overall estimated incidence rates of kidney cancer and urothelial cancers are 0.4% and 0.5%, respectively. There is a significant positive correlation between the incidence of urologic malignancies and year of study.

AB - Aim: Previous studies have suggested a higher incidence of urologic malignancies in end-stage renal disease (ESRD) patients. However, incidence trends of urologic malignancies in ESRD patients remain unclear. The aims of the present study were: (i) to investigate the pooled incidence/incidence trends; and (ii) to assess the risk of urologic malignancies in ESRD patients. Methods: A literature search was conducted using MEDLINE, EMBASE and Cochrane Database from inception through April 2017. Studies that reported incidence or odds ratios of urologic malignancies among ESRD patients were included. Pooled odds ratios (OR) and 95%CI were calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067687). Results: Nineteen observational studies with 1 931 073 ESRD patients were enrolled. The pooled estimated incidence of kidney cancer and urothelial cancers (carcinomas of the bladder, ureters, and renal pelvis) in ESRD patients were 0.3% (95%CI: 0.2–0.5%) and 0.5% (95%CI: 0.3–0.8%), respectively. Meta-regression showed significant positive correlation between incidence of urologic malignancies in ESRD patients and year of study (slopes = +0.05 and +0.07, P < 0.001 for kidney cancer and urothelial cancers, respectively). Compared to non-ESRD status, ESRD was significantly associated with both kidney cancer (pooled OR 6.04; 95% CI 4.70–7.77) and urothelial cancers (pooled OR 4.37; 95% CI 2.40–7.96). Conclusion: Our study demonstrates a significant association between ESRD and urologic malignancies. The overall estimated incidence rates of kidney cancer and urothelial cancers are 0.4% and 0.5%, respectively. There is a significant positive correlation between the incidence of urologic malignancies and year of study.

KW - bladder cancer

KW - end-stage kidney disease

KW - kidney cancer

KW - meta-analysis

KW - urologic malignancies

UR - http://www.scopus.com/inward/record.url?scp=85058676643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058676643&partnerID=8YFLogxK

U2 - 10.1111/nep.13209

DO - 10.1111/nep.13209

M3 - Article

VL - 24

SP - 65

EP - 73

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 1

ER -